Rhythm Biosciences welcomes leading biotechnology investor Merchant Group as a substantial holder, buying at between $0.18 and 0.21, average 0.1915 (Refer Annexure A).

The Merchant Opportunities Fund, which now holds 5,060,000 FPO or 5.02 percent of Rhythm (up from 2,200,000 units as reported on Sprout8 Twitter on 22/5), has long been recognised as a successful, long term investor in biotechnology companies that are close to commercialisation. 

Merchant have long been recognised as a successful long term investor in biotech plays that are close to commercialisation.